Mylan, Apple lose US Supreme Court bids to challenge patent review rule
Advertisement
The U.S. Supreme Court on Tuesday turned back challenges by Apple Inc and drugmaker Mylan Laboratories Ltd to a rule change that made it harder to contest patents before the U.S. Patent and Trademark Office.
The internal rule, adopted in 2020 under former PTO director Andrei Iancu, gives judges at the agency's Patent Trial and Appeal Board greater discretion to reject challenges to the validity of specific patents.
For more information, check out the full story on the link below:
Apple, Mylan lose US SC bids to challenge patent review rule
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.